Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the afirma gene expression classifier in cytologically indeterminate thyroid nodules?

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages

  Kloos, Richard T ^a   Reynolds, Jessica D ^a   Walsh, P Sean ^a   Wilde, Jonathan I ^a   Tom, Edward Y ^a   Pagan, Moraima ^a   Barbacioru, Catalin ^a   Chudova, Darya I ^a   Wong, Mei ^a   Friedman, Lyssa ^a   LiVolsi, Virginia A ^b   Rosai, Juan ^c   Lanman, Richard B ^a   Kennedy, Giulia C ^a  

^a Veracyte Inc   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Centro Diagnostico Italiano   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE;

ARTICLE; BENIGN TUMOR; CLASSIFIER; CONTROLLED STUDY; CYTOLOGICALLY INDETERMINATE THYROID NODULE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA EXTRACTION; ENZYME ASSAY; FALSE NEGATIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MUTATIONAL ANALYSIS; PREVALENCE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THYROID FOLLICULAR CARCINOMA; THYROID NODULE;

AMINO ACID SUBSTITUTION; BIOPSY, FINE-NEEDLE; CYTOLOGICAL TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENETIC TESTING; GLUTAMIC ACID; HT29 CELLS; HUMANS; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NODULE; VALINE;

EID: 84876215929     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3762     Document Type: Article

References (34)

1. Cooper DS, Doherty GM, Haugen B.R., et al Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167-1214.
2. Baloch ZW, Fleisher S, LiVolsi V.A., Gupta PK Diagnosis of "fol-licular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002; 26:41-44.
3. Cibas ES, Ali SZ The Bethesda System for Reporting Thyroid Cy-topathology. Am J Clin Pathol. 2009; 132:658-665.
4. Gharib H, Papini E, Paschke R., et al American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendations. J Endocrinol Invest. 2010; 33:287-291.
5. Tuttle RM, Ball DW, Byrd D, et al Thyroid carcinoma. J Natl Compr Canc Netw. 2010; 8:1228-1274.
6. Wang CC, Friedman L, Kennedy G.C., et al A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011; 21:243-251.
7. Chudova D, Wilde JI, Wang E.T., et al Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010; 95:5296-5304.
8. Alexander EK, Kennedy GC, Baloch Z.W., et al Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. N Engl J Med. 2012; 367:705-715.
9. Walsh PS, Wilde JI, Tom E.Y., et al Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules. J Clin Endocrinol Metab. 2012; 97:E2297-E2306.
10. Monroe R, Zalles C, Traweek T., O'Reilly KO, et al Clinical practice impact of a novel mRNA-based gene expression classifier in thyroid nodules with indeterminate fine needle aspiration cytology. Thyroid. 2011; 21:A-101.
11. Duick DS, Klopper J, Diggans J.C., et al The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate FNA cytopathology. Thyroid. 2012; 22:996-1001.
12. Li H, Robinson KA, Anton B, Saldanha I.J., Ladenson PW Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2011; 96:E1719-E1726.
13. Nikiforov YE, Ohori NP, Hodak S.P., et al Impact of mutational testing on the diagnosis and management of patients with cytolog-ically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011; 96:3390-3397.
14. Kleiman DA, Sporn MJ, Beninato T, et al Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients [published online 21 December 2012]. Cancer. doi:10.1002/cncr.27888.
15. V600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab. 2012; 97:2295-2298.
16. Navidi W, Arnheim N, Waterman MS A multiple-tubes approach for accurate genotyping of very small DNA samples by using PCR: statistical considerations. Am J Hum Genet. 1992; 50:347-359.
17. Walsh PS, Erlich HA, Higuchi R. Preferential PCR amplification of alleles: mechanisms and solutions. PCR Methods Appl. 1992; 1: 241-250.
18. Yip L, Farris C, Kabaker A.S., et al Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab. 2012; 97:1905-1912.
19. National Comprehensive Cancer Network. Thyroid carcinoma guidelines, version 1. 2013. http://nccn.org. Accessed January 7, 2013.
20. Lewis CM, Chang KP, Pitman M, Faquin W.C., Randolph GW Thyroid fine-needle aspiration biopsy: variability in reporting. Thyroid. 2009; 19:717-723.
21. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011; 96:2016-2026.
22. Jameson JL. Minimizing unnecessary surgery for thyroid nodules. N Engl J Med. 2012; 367:765-767.
23. Tomei S, Marchetti I, Zavaglia K., et al A molecular computational model improves the preoperative diagnosis of thyroid nodules. BMC Cancer. 2012; 12:396.
24. Bossuyt PM, Reitsma JB, Bruns D.E., et al Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol. 2003; 119:18-22.
25. Lee JH, Lee ES, Kim YS Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007; 110:38-46.
26. Nikiforova MN, Nikiforov YE Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009; 19:1351-1361.
27. Melck AL, Yip L, Carty SE The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010; 15:1285-1293.
28. Xing M, Clark D, Guan H., et al BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009; 27:2977-2982.
29. Proietti A, Giannini R, Ugolini C., et al BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Thyroid. 2010; 20:1263-1270.
30. Smith GD, Zhou L, Rowe L.R., et al Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens. Acta Cytol. 2011; 55:576-583.
31. Applied Biosystems. Mutation detection with high sensitivity and specificity. http://www.appliedbiosystems.com/absite/us/en/home/applications- technologies/real-time-pcr/castpcr.printable.html. Accessed January 11, 2012.
32. Lee ST, Kim SW, Ki C.S., et al Clinical implication of highly sensitive detection of the BRAF V600E mutationin fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab. 2012; 97:2299-2306.
33. V600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab. 2012; 97:2333-2340.
34. Nikiforov YE, Nikiforova MN Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011; 7:569-580.